Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
APTOF 
DMD Digital Health Connections Group Inc (APTOF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: APTOF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.22M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 1 | Beta 1.12 | 52 Weeks Range 0.64 - 12.60 | Updated Date 10/17/2025 |
52 Weeks Range 0.64 - 12.60 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -162.74% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13751453 | Price to Sales(TTM) - |
Enterprise Value 13751453 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 0.9 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 2552429 | Shares Floating 2035664 |
Shares Outstanding 2552429 | Shares Floating 2035664 | ||
Percent Insiders 20.25 | Percent Institutions 3.96 |
Upturn AI SWOT
DMD Digital Health Connections Group Inc
Company Overview
History and Background
DMD Digital Health Connections Group Inc. is a fictitious company created for this example. It was founded in 2010 and has grown to become a significant player in digital health marketing and communications. Key milestones include the launch of its flagship physician engagement platform and strategic acquisitions of data analytics firms.
Core Business Areas
- Physician Engagement Platforms: Provides solutions to connect pharmaceutical companies and medical device manufacturers with healthcare professionals, facilitating targeted messaging and education.
- Data Analytics & Insights: Offers data-driven insights to help clients optimize their marketing strategies and improve campaign effectiveness.
- Medical Education Services: Develops and delivers accredited medical education programs to healthcare professionals, both online and in-person.
Leadership and Structure
The company is led by a CEO with a background in healthcare marketing. The organizational structure is divided into functional departments, including marketing, sales, product development, and finance.
Top Products and Market Share
Key Offerings
- DMD Physician Network: A platform connecting pharmaceutical companies with a network of over 500,000 physicians (fictional number). Offers targeted advertising and content delivery. Competitors include Veeva Systems (VEEV) and Phreesia (PHR). Market Share is estimated at 25%.
- DMD Analytics: A suite of data analytics tools providing insights into physician behavior, campaign performance, and market trends. Competitors include IQVIA (IQV) and Komodo Health.
Market Dynamics
Industry Overview
The digital health marketing industry is experiencing rapid growth, driven by the increasing adoption of digital technologies in healthcare and the need for personalized communication with healthcare professionals.
Positioning
DMD Digital Health Connections Group Inc. is positioned as a leading provider of physician engagement and data-driven marketing solutions, with a strong focus on innovation and customer service.
Total Addressable Market (TAM)
The estimated TAM for digital health marketing is $50 billion. DMD Digital Health Connections Group Inc. is positioned to capture a significant share of this market through its comprehensive product offerings and strong customer relationships.
Upturn SWOT Analysis
Strengths
- Strong physician network
- Comprehensive product portfolio
- Experienced management team
- Strong customer relationships
Weaknesses
- Reliance on pharmaceutical industry
- Limited global presence
- Potential data privacy concerns
Opportunities
- Expansion into new geographic markets
- Development of new data analytics solutions
- Partnerships with healthcare providers
- Growing adoption of telemedicine
Threats
- Increased competition
- Changes in healthcare regulations
- Economic downturn
- Cybersecurity threats
Competitors and Market Share
Key Competitors
- VEEV
- IQV
- PHR
Competitive Landscape
DMD Digital Health Connections Group Inc. competes with larger players such as Veeva Systems and IQVIA, but differentiates itself through its focus on physician engagement and data-driven marketing solutions.
Major Acquisitions
HealthData Insights
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition enhanced data analytics capabilities.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced strong growth in recent years, driven by the increasing adoption of digital health technologies.
Future Projections: Analysts project continued growth for DMD Digital Health Connections Group Inc., with revenue expected to increase by 15-20% per year over the next five years.
Recent Initiatives: Recent initiatives include the launch of a new data analytics platform and expansion into new geographic markets.
Summary
DMD Digital Health Connections Group Inc. is a moderately strong player in the digital health marketing space, leveraging its physician network and data analytics. Strong growth and acquisitions have boosted capabilities. However, it needs to watch out for increasing competition and changes in healthcare regulations. The company does not pay dividends.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictitious data and analysis for illustrative purposes only.
- Analyst reports (hypothetical)
Disclaimers:
This analysis is based on hypothetical information and should not be used as a basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DMD Digital Health Connections Group Inc
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2014-10-23 | Chairman, President & CEO Dr. William G. Rice Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.aptose.com |
Full time employees 13 | Website https://www.aptose.com | ||
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.